【Can-Fite BioPharma- Product CF102】Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis

Partner News

18 May, 2020–
Can-Fite BioPharma Ltd. issued an announcement, which is summarized as follows:

cases of NASH significantly resolved after 12 weeks of treatment with
Namodenoson 25 mg

safety profile and efficacy in Phase II position the drug for advanced clinical
trials in the treatment of NAFLD/NASH, a projected $35 billion market by 2025

Can-fite today announced
additional findings from its Phase II study of Namodenoson in the treatment of
patients with non-alcoholic fatty liver disease (NAFLD) with or without
non-alcoholic steatohepatitis (NASH). On April 7, the Company reported topline
results from the Phase II study indicating Namodenoson had achieved its
efficacy endpoints in a dose dependent and statistically significant manner,
while continuing to demonstrate a good safety profile. Most significantly, a
more recent in-depth review of the Phase II data reveal 25 mg of Namodenoson
was found to resolve significantly all cases of NASH, representing 25% of the
25 mg treated group, as compared to an increase in new NASH cases in the
placebo group from a baseline of 0 to 5.9%.

In the Phase II study, 25
mg of Namodenoson was shown to reduce hepatic fibrosis (scar tissue in the
liver resulting from the liver trying to repair itself), reduce steatosis (fat
buildup in the liver), and improve the FAST score, a measure for NASH (liver
stiffness and an enzymatic biomarker of liver damage).

data show that Namodenoson reversed and eliminated NASH, and may prevent the progression
of NAFLD into NASH. We are very pleased and impressed by these results. Given
the clear need for approved drugs in this indication, we believe Namodenoson is
a strong candidate for advanced stage clinical development as a treatment for
both NAFLD and NASH,” stated Prof. Rifaat Safadi of Hadassah Medical Center,
the Principal Investigator of the study.

The original website link: